Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves a slightly higher rate of complications vs. non-CTO PCI. 

Revascularization impact on left ventricular ejection fraction (LVEF) varies across studies. For instance, the EXPLORE and REVASC trials did not find improved LVEF, LV end-diastolic volume, or segmental wall thickening. However, other studies and meta-analyses have reported certain improvement, especially in patients with prior ventricular function deterioration. 

One study done on 142 CTO patients showed PCI was successful (SPCI) in 121 of them (85.2%).

The groups had similar baseline characteristics, though patients with failed PCI (FPCI) were older (64.6 vs. 69.7 years, p=0.008) and presented longer fluoroscopy time (55.7 vs. 37.7 minutes, p<0.001).

Women represented one third of the population. There were no significant differences in prevalence of hypertension (97%), diabetes (51%), prior PCI (62%), prior myocardial revascularization surgery (21%), stroke (24%), atrial fibrillation (29%), COPD (11%), kidney dysfunction (47%) or need for dialysis (10%). Mean initial LVEF was 49%, with 37% of patients presenting ≤50% and 23% with ≤30%. 

Read also: TAVR and Surgical Bailout: Temporal Trends and Clinical Implications.

The right coronary was the most affected artery (50%), followed by the anterior descending (31.7%) and the circumflex (18.3%).

Average J-CTO was 2: 0 in 9.2%, 1 in 19.7%, 2 in 43.7% and ≥3 in the rest of cases. Mean procedural time was 107 minutes, with 222 ml contrast volume.

Results at Followup 

Median time from PCI to follow-up echocardiogram was 8.4 months; SPCI patients saw a significant increase in LVEF (48.2% to 51.8%, p<0.001), with 29% showing ≥10% improvement. On the contrary, in patients with FPCI, there was no LVEF increase or deterioration. 

Read also: Timing in Complete Revascularization in Acute Coronary Syndrome: BIOVASC 2-Year Followup.

Among patients with <50% baseline LVEF (n=50) and SPCI, there was significant improvement (32.6% to 40%, p<0.001), and 24 of these patients saw a ≥10% increase. Even though there was an non-significant improvement in functional class according to the Canadian Cardiovascular Society, there were no changes according to New York Heart Association.

The general population did not see target vessel related changes in LVEF with SPCI. However, patients with <50% LVEF saw notable target vessel related improvement:

  • Anterior Descending: 9.4%.
  • Circumflex: 6.3%.
  • Right Coronary: 7.3%.

 

At multivariable analysis, SPCI was a significant predictor of improved LVEF (≥10%) in patients with baseline ventricular function deterioration. However, CTO localization was not a relevant predictor of improved LVEF.

Conclusion

Successful CTO- PCI is associated with modest improvement of left ventricular ejection fraction, more pronounced in patients with reduced baseline LVEF. 

Original Title: Assessment of Left Ventricular Function After Percutaneous Coronary Intervention for Chronic Total Occlusion. 

Reference: Yasser M. Sammour, et, al. Journal of the Society for Cardiovascular Angiography & Interventions 4 (2025) 102460 https://doi.org/10.1016/j.jscai.2024.102460.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...